• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The annual cost of psoriasis.

作者信息

Sander H M, Morris L F, Phillips C M, Harrison P E, Menter A

机构信息

Baylor Psoriasis Center, Dallas, TX 75246.

出版信息

J Am Acad Dermatol. 1993 Mar;28(3):422-5. doi: 10.1016/0190-9622(93)70062-x.

DOI:10.1016/0190-9622(93)70062-x
PMID:8445058
Abstract

BACKGROUND

The need for comparative cost figures for psoriasis therapy has become increasingly important.

OBJECTIVE

Our purpose was to compare the yearly costs of various psoriasis treatments.

METHODS

Ten patients were selected for each treatment modality and the average total cost per year, per patient was evaluated.

RESULTS

All treatments evaluated were cheaper than inpatient therapy, with Goeckerman treatment in the day-care setting the most expensive and hydroxyurea the cheapest. Cyclosporine, which was used for comparison, was at least twice as expensive as all the other treatments except for Goeckerman treatment in the day-care setting, compared with which it was about 70% more expensive.

CONCLUSION

No single treatment appears to be universally superior to others. In considering specific treatment for psoriasis, cost analyses, including appropriate laboratory and other specialized evaluations, must be taken into account. With use of these data, practitioners and health care organizations may be better able to select appropriate therapy.

摘要

相似文献

1
The annual cost of psoriasis.
J Am Acad Dermatol. 1993 Mar;28(3):422-5. doi: 10.1016/0190-9622(93)70062-x.
2
Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.中度至重度银屑病的全身治疗:美国东北部管理式医疗计划中的失败率估计和直接医疗成本
J Dermatolog Treat. 2005 Feb;16(1):37-42. doi: 10.1080/09546630510025941.
3
[Cost Effectiveness of Treatments of Psoriasis with a PASI 75 and one Period of 12 Weeks].[达到银屑病面积和严重程度指数(PASI)改善75%且治疗周期为12周的银屑病治疗方案的成本效益分析]
Rev Esp Salud Publica. 2016 Apr 13;90:E15.
4
[Cost-effectiveness analysis comparing methotrexate with PUVA therapy for moderate-severe psoriasis in the sanitary area of Badajoz].[巴达霍斯卫生区甲氨蝶呤与补骨脂素紫外线A光化学疗法治疗中重度银屑病的成本效益分析]
Actas Dermosifiliogr. 2007 Jan-Feb;98(1):35-41.
5
Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis.美国食品和药物管理局批准的用于治疗中重度银屑病的系统治疗的成本效益估计。
J Am Acad Dermatol. 2015 Apr;72(4):589-98. doi: 10.1016/j.jaad.2014.11.028. Epub 2015 Jan 25.
6
Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.管理式医疗体系中降低成本措施对重度银屑病治疗的矛盾效应。
Dermatol Online J. 2009 Apr 15;15(4):1.
7
A 61-year-old man with psoriasis.一名61岁的银屑病男性患者。
JAMA. 1996 Nov 6;276(17):1421-8.
8
Retrospective analysis of the effectiveness and costs of traditional treatments for moderate-to-severe psoriasis: A single-center, Italian study.中重度银屑病传统治疗方法的有效性和成本的回顾性分析:一项意大利单中心研究。
J Dermatolog Treat. 2016 Oct;27(5):399-405. doi: 10.3109/09546634.2015.1133885. Epub 2016 Jan 28.
9
Cost-effectiveness and cost-benefit analysis of using methotrexate vs Goeckerman therapy for psoriasis. A pilot study.甲氨蝶呤与格克曼疗法治疗银屑病的成本效益和成本效益分析。一项初步研究。
Arch Dermatol. 1998 Dec;134(12):1602-8. doi: 10.1001/archderm.134.12.1602.
10
Treatment of psoriasis. Results achieved by the Johannesburg Hospital Psoriasis Clinic.
S Afr Med J. 1986 Jan 4;69(1):23-6.

引用本文的文献

1
Psychological Stress and the Cutaneous Immune Response: Roles of the HPA Axis and the Sympathetic Nervous System in Atopic Dermatitis and Psoriasis.心理应激与皮肤免疫反应:下丘脑-垂体-肾上腺轴和交感神经系统在特应性皮炎和银屑病中的作用
Dermatol Res Pract. 2012;2012:403908. doi: 10.1155/2012/403908. Epub 2012 Aug 30.
2
Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin.全基因组表达分析揭示了未受累银屑病皮肤中脂质生物合成减少和固有免疫增加的证据。
J Invest Dermatol. 2009 Dec;129(12):2795-804. doi: 10.1038/jid.2009.173. Epub 2009 Jul 2.
3
Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis.
全基因组关联扫描为银屑病的免疫发病机制带来新见解。
Genes Immun. 2009 Apr;10(3):201-9. doi: 10.1038/gene.2009.11. Epub 2009 Mar 5.
4
Moderate and severe plaque psoriasis: cost-of-illness study in Italy.中重度斑块状银屑病:意大利疾病经济负担研究。
Ther Clin Risk Manag. 2008 Apr;4(2):559-68. doi: 10.2147/tcrm.s2740.
5
The economics of topical immunomodulators for the treatment of atopic dermatitis.用于治疗特应性皮炎的局部免疫调节剂的经济学
Pharmacoeconomics. 2005;23(6):543-66. doi: 10.2165/00019053-200523060-00003.
6
Amphiregulin and epidermal hyperplasia: amphiregulin is required to maintain the psoriatic phenotype of human skin grafts on severe combined immunodeficient mice.双调蛋白与表皮增生:双调蛋白是维持严重联合免疫缺陷小鼠上人类皮肤移植片银屑病表型所必需的。
Am J Pathol. 2005 Apr;166(4):1009-16. doi: 10.1016/S0002-9440(10)62322-X.
7
Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus.利用基于密集单核苷酸多态性的图谱进行的家系分析确定了主要银屑病易感基因座PSORS1的遗传变异。
Am J Hum Genet. 2002 Sep;71(3):554-64. doi: 10.1086/342289. Epub 2002 Jul 29.
8
Cost-effectiveness analysis of topical calcipotriol versus short-contact dithranol. In the treatment of mild to moderate plaque psoriasis.外用卡泊三醇与短期接触蒽林治疗轻度至中度斑块状银屑病的成本效益分析
Pharmacoeconomics. 2000 Nov;18(5):469-76. doi: 10.2165/00019053-200018050-00006.